Overall, as shown in Figure 3, we identified that COVID-19 patients with severe/critical disease presented significantly higher urinary levels of IL-1β, IL-4, IL-6, IL-7, IL-16, IL-17A, LIF, CCL-2, CCL-3, CCL-11, CXCL-10, FGFb, M-CSF, and CTAcK when compared to HC and/or COVID-19 patients with mild/moderate disease. This evidence concerns the gene FGF2 and COVID-19.